# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncolog...
Leerink Partners analyst Daina Graybosch initiates coverage on I-MAB (NASDAQ:IMAB) with a Outperform rating and announces Pr...
BTIG analyst Justin Zelin reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $7 price target.